Renal cell carcinoma in Ireland: rising mortality and survival

2018 ◽  
Vol 12 (3) ◽  
pp. 217-222
Author(s):  
Lee Chien Yap ◽  
Frank Leonard ◽  
Ivor Cullen ◽  
Padraig Daly
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Developed Countries ◽  
Mortality Rates ◽  
Percentage Change ◽  
Annual Percentage Change ◽  
Level Of Evidence ◽  
Female Population ◽  
Incidence And Mortality

Objective: The objective of this study was to evaluate the rising trend in the incidence and mortality of renal cell carcinoma in Ireland. Methods: Data from the National Cancer Registry of Ireland on primary adenocarcinomas of the kidney from 2003 to 2013 were evaluated. Statistical analysis was performed on the data using IBM SPSS statistics V24 software package and Microsoft Excel Software. Results: There were 3801 cases of adenocarcinoma of the kidney with 29% of tumours (n=1103) being found incidentally. The age-adjusted incidence rate of renal cell carcinoma in 2003 was 4.66 per 100,000 women and 8.78 per 100,000 men. These figures have risen to 5.78 and 13.14 in 2013, respectively. There was an annual percentage change of +2.2% for women and +4.1% for men from the years 2003 to 2013. For both sexes the age-standardised all-cause mortality rate for renal adenocarcinoma increased from 1.07 per 100,000 in 2003 to 4.32 ± 0.06 per 100,000 in 2013, an annual percentage change of +15%. Age-adjusted mortality rates in the female population in Ireland increased from 0.78 to 2.66, an annual percentage change of +13.1% and from 1.41 to 6.04 in men, an annual percentage change of +15.8%. Conclusion: There is a paradox emerging in Ireland, with both rising survival rates for renal cell carcinoma and rising mortality rates. While the increased incidence of renal cell carcinoma in Ireland can be attributed somewhat to the increased use of various imaging modalities, it may also be attributed to the significant rise in modifiable risk factors as seen in other developed countries, namely hypertension, obesity, and smoking. Level of evidence: 2c

Incidence and mortality of renal cell carcinoma in the U.S.: A SEER-based study investigating trends over the last four decades.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 604-604
Author(s):  
Mohamed M Gad ◽  
Anas M Saad ◽  
Muneer J Al-Huseini ◽  
Inas A. Ruhban ◽  
Mohamad B. Sonbol
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Seer Database ◽  
Distant Disease ◽  
Cell Subtype ◽  
Incidence And Mortality

604 Background: Renal cell carcinoma (RCC) is the third most common urologic malignancy worldwide, with clear cell subtype being the most common. In this study, we sought to investigate RCC incidence and mortality trends by demographic and tumor characteristics using data from the surveillance, epidemiology and end results (SEER) database. Methods: We used SEER database to study RCC cases between 1973 and 2014. Incidence and mortality rates were calculated by sex, age, race, state, stage, size, and histological subtype of RCC. Annual percent change (APC) was calculated using joinpoint regression software. Results: A total of 96,058 RCC cases were identified, with 54,000 RCC deaths between 1973 and 2014. Overall incidence was 9.712 per 100,000 persons-years, being highest among males (13.698), blacks (11.886), and people older than 65 years (38.693). Incidence rates of localized cases (5.845) and tumors smaller than 7 cm (6.550) were higher than other tumor subgroups with distant disease incidence of 1.773 per 100,000 persons-years. Overall incidence rates increased by 2.709% (95% CI, 2.544-2.875, p < .001) per year over the study period, but rates became stable since 2007 with only an increase in the incidence of clear-cell subtype (2.538%; 95% CI, 1.300-3.791, p < .001). Overall RCC mortality rates have been declining since 2000, and distant disease mortality have been decreasing since 2008 with most profound decline in the period between 2012 and 2014 with APC of -22.635% (-37.419- -4.359, P = .019) Conclusions: Despite overall increase in rates over the last 40 years, recent years have shown stable incidence and decrease in mortality rates of RCC. The significant decline in mortality over the last 10 years since the approval of the first Vascular Endothelial Growth Factor ‘VEGF’ inhibitor highlights the impact of this class of medications along with other subsequent agents such as mTOR inhibitors and checkpoint inhibitors on the prognosis of renal cell carcinoma.

1299 CONTEMPORARY INCIDENCE AND MORTALITY RATES OF RENAL CELL CARCINOMA IN THE UNITED STATES

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Maxine Sun ◽  
Vincent QH Trinh ◽  
Florian Roghmann ◽  
Andreas Becker ◽  
Hugo Lavigueur-Blouin ◽  
...  
Keyword(s):  
United States ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
The United States ◽  
Mortality Rates ◽  
Incidence And Mortality

scholarly journals Determination of Expression Signature and Proportion of mtDNA in Plasma Fractions in Patients with Renal Cell Carcinoma

Proceedings ◽  
2020 ◽  
Vol 76 (1) ◽  
pp. 9
Author(s):  
Elena Arance-Criado ◽  
Fernando Vázquez-Alonso ◽  
Mª Yarmila García-Iglesias ◽  
Rocío López-Cintas ◽  
Sara Martín-Esteban ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Fragment Size ◽  
Predictive Biomarkers ◽  
Developed Countries ◽  
P Value ◽  
Mtdna Copy Number ◽  
Incidence And Mortality ◽  
Plasma Fractions

Renal Cell Carcinoma (RCC) is the third most common urologic malignancy, remaining one of the most lethal urological malignancies, preferably in developed countries. The incidence and mortality rates differ significantly according to sex, race, age and external factors such as smoking, obesity and hypertension increasing RCC risk. The use of novel predictive biomarkers is currently being increased as these improve the diagnosis, progression and prognosis of RCC. Since recent studies have demonstrated a promising association between mitochondrial DNA (mtDNA) copy number alteration in peripheral blood and the risk of developing RCC, we conducted a case-control study into a cohort of 15 controls and 13 patients to determine exosomes mtDNA content in plasma fractions as a potential novel non-invasive biomarker in liquid biopsy in order to monitor the RCC status in patients. In this way, plasma fractions highly purified in exosomes were obtained from blood samples from controls and RCC cases, and relative mtDNA content was measured by quantitative real-time polymerase chain reaction (qPCR). Our results show fragment size distribution profile and we observed that in phase F; with a higher content of exosomal mtDNA; p value shows statistically significant differences in mitochondrial genes HV long and CYB long

NON-CANCER RELATED MORTALITY RATES IN EUROPEAN PATIENTS WITH T1A AND T1B RENAL CELL CARCINOMA

2009 ◽  
Vol 181 (4S) ◽  
pp. 469-469
Author(s):  
Laurent Zini ◽  
Jean-Jacques Patard ◽  
Umberto Capitanio ◽  
Maxime Crepel ◽  
Alexandre de la Taille ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mortality Rates ◽  
Related Mortality

scholarly journals A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Fan Li ◽  
Weifeng Hu ◽  
Wei Zhang ◽  
Guohao Li ◽  
Yonglian Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Malignant Tumors ◽  
Prognostic Significance ◽  
Gene Signature ◽  
The Cancer Genome Atlas ◽  
Prognostic Indicators ◽  
Incidence And Mortality ◽  
Tcga Dataset

Renal cell carcinoma (RCC), which was one of the most common malignant tumors in urinary system, had gradually increased incidence and mortality in recent years. Although significant advances had been made in molecular and biology research on the pathogenesis of RCC, effective treatments and prognostic indicators were still lacking. In order to predict the prognosis of RCC better, we identified 17 genes that were associated with the overall survival (OS) of RCC patients from The Cancer Genome Atlas (TCGA) dataset and a 17-gene signature was developed. Through SurvExpress, we analyzed the expression differences of the 17 genes and their correlation with the survival of RCC patients in five datasets (ZHAO, TCGA, KIPAN, KIRC, and KIRP), and then evaluated the survival prognostic significance of the 17-gene signature for RCC. Our results showed that the 17-gene signature had a predictive prognostic value not only in single pathologic RCC, but also in multiple pathologic types of RCC. In conclusion, the 17-gene signature model was related to the survival of RCC patients and could help predict the prognosis with significant clinical implications.

scholarly journals Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

2013 ◽  
Vol 13 (1) ◽  
pp. 63-70
Author(s):  
Ieva Vaivode ◽  
Vilnis Lietuvietis ◽  
Alinta Hegmane ◽  
Iveta Kudaba
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Accuracy ◽  
Treatment Strategies ◽  
Simple Algorithm ◽  
Mortality Data ◽  
Routine Practice ◽  
Clinical Scenarios ◽  
Incidence And Mortality

Summary Morbidity and mortality data of RCC (renal cell carcinoma) differs a lot among the European countries. In Latvia a growing trend in both incidence and mortality rates is still observed. The expanding availability of multiple treatment strategies has increased the importance of skilled individualized outcome prediction for patients. Several prognostic factors are available in RCC including anatomical, histological, clinical and molecular ones, but none of them is very precise, when used alone. Therefore increasing number of prognostic systems has been created in local and metastatic disease to increase predictive accuracy. In order to encourage the clinicians to use the available models in their routine practice, we tried to select the most relevant ones and include them in a simple algorithm to be used in common clinical scenarios throughout entire history of the disease in patients with RCC

scholarly journals Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?

2014 ◽  
Vol 1 (8) ◽  
pp. 84-98 ◽  
Author(s):  
Ana L Teixeira ◽  
Francisca Dias ◽  
Mónica Gomes ◽  
Mara Fernandes ◽  
Rui Medeiros
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Genetic Material ◽  
Tumor Development ◽  
Cell Communication ◽  
Bioactive Molecules ◽  
Screening Tests ◽  
Transcriptional Level ◽  
Incidence And Mortality

Renal cell carcinoma (RCC) is a lethal urological cancer, with incidence and mortality rates increasing by 2-3% per decade. The lack of   standard screening tests contributes to the fact that one-third of patients are diagnosed with locally invasive or metastatic disease. Moreover, 20-40% of RCC patients submitted to surgical nephrectomy will develop metastasis. MicroRNAs (miRNAs) are small non-coding RNAs responsible for gene regulation at a post-transcriptional level.  It is accepted that they are deregulated in cancer and can influence tumor development. Thus, miRNAs are promising RCC biomarkers, since they can be detected using non-invasive methods. They are highly stable and easier to quantify in circulating biofluids. The elevated miRNA stability in circulating samples may be the consequence of their capacity to circulate inside of extracellular microvesicles (EMVs), for example, the exosomes.  The EMVs are bilayered membrane vesicles secreted by all cell types. They can be released in the interstitial space or into circulating biofluids, which allows the travelling, binding and entrance of these vesicles in receptor cells. This type of cell communication can shuttle bioactive molecules between cells, allowing the horizontal transference of genetic material. In this review, we focus on circulating miRNAs (miR-210, miR-1233, miR-221, miR-15a, miR-451, miR-508, miR-378) in the biofluids of RCC patients and attempt to establish the diagnostic and prognostic accuracy, their synergic effects, and the pathways involved in RCC biology.

scholarly journals Renal cell carcinoma at the time of presentation: a 5-year radiological survey at a tertiary care cancer hospital

2020 ◽  
Vol 7 (5) ◽  
pp. 1657
Author(s):  
Muhammad Omer Altaf ◽  
Asma Riaz ◽  
Mehreen Shafqat ◽  
Hamd Zahra ◽  
Naila Iqbal ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tertiary Care ◽  
Developed Countries ◽  
Nodal Metastasis ◽  
Male Predominance ◽  
Cancer Hospital ◽  
Stage 1 ◽  
Time Of Presentation

Background: Renal cell carcinoma (RCC) is associated with highest mortality rates of all the genitourinary tumors with increased incidence in the past few decades. It is heterogenous tumor with several histological types. Main diagnostic approach is radiological imaging followed by histopathology.Methods: It is a retrospective study conducted at a tertiary care cancer hospital in Pakistan. We reviewed the record of all the RCC patients in terms of age, gender, radiological manifestation of tumor size, polarity, laterality, stage including nodal status, metastasis and histological type.Results: Our study included 149 patients of RCC. Mean age of presentation was 57 years with a male predominance. The most common stage of presentation was stage 3 seen in 41% patients followed by stage 1 in 37% patients. nodal metastasis was observed in around 13% patients and distant metastasis in 8% patients. Also, majority of the patient had histological subtype of clear cell CA (63%) followed by papillary CA (33%).Conclusions: Epidemiological features of renal cell CA are observed over a period of 5 years representing our population. The current trends show variation from those observed in developed countries depicting the struggle of healthcare awareness in developing countries.

scholarly journals RENAL CELL CARCINOMA METASTASIS OF THE SPINE: BLEEDING CONTROL METHODS

2018 ◽  
Vol 17 (3) ◽  
pp. 233-236
Author(s):  
Nikita Zaborovskii ◽  
Dmitrii Ptashnikov ◽  
Dmitrii Mikaylov ◽  
Sergei Masevnin ◽  
Oleg Smekalenkov
Keyword(s):  
Renal Cell Carcinoma ◽  
Retrospective Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Spinal Metastasis ◽  
Preoperative Embolization ◽  
Control Methods ◽  
Bleeding Control ◽  
Level Of Evidence ◽  
Combination Of Methods

ABSTRACT Objective: This report compares various methods of bleeding control, and their influence on outcome and survival after decompression procedures for spinal metastasis of renal cell carcinoma (MRCC). Methods: A retrospective study. All patients underwent palliative decompression procedures. We compared 3 groups of patients stratified by methods of bleeding control. The first group (EMB) included 22 patients who underwent preoperative embolization of a tumor. The second group (HEM) consisted of 20 patients, treated surgically using intraoperative local hemostatic agents. In the third group (COMBI) 15 patients were treated with a combination of methods. Results: The average intraoperative blood loss for the EMB group was slightly less than the average for the HEM and COMBI groups, but without significant differences. The postoperative drainage loss in the HEM and COMBI groups was significantly less than in EMB group. The complication rate (infections, hematomas, neurological deficit) was practically equal in all groups. No statistically significant differences in local tumor recurrence and overall survival were found between groups. Conclusions: The overall results did not show that usage of different bleeding control methods can affect early or long-term outcomes. Level of Evidence III; retrospective study.

Sign in / Sign up

Export Citation Format

Share Document